

## Effects of delayed consent on patient characteristics in adult patients with sepsis [Letter]

**Frank Bloos, Holger Bogatsch, Mihai G. Netea, Evangelos J. Giamarellos-Bourboulis, Michael Bauer, Ulrich Jaschinski, Simon Philipp, Christian Putensen, Maximilian Ragaller, Mathias Gründling, Sven Olaf Kuhn, Harald Fritz, Dominik Jarzcak, Geraldine Heer, Stefan Kluge, Axel Nierhaus, Johann Motsch, Daniel C Richter, Daniel Thomas-Rüddel, Gunnar Elke, Dirk Schaedler, Norbert Weiler, Gunther Hempel, Sebastian Stehr, Joseph Briegel, Raphael Weiss, Andreas Weyland, Patrick Meybohm, Reimer Riessen**

### Angaben zur Veröffentlichung / Publication details:

Bloos, Frank, Holger Bogatsch, Mihai G. Netea, Evangelos J. Giamarellos-Bourboulis, Michael Bauer, Ulrich Jaschinski, Simon Philipp, et al. 2025. "Effects of delayed consent on patient characteristics in adult patients with sepsis [Letter]." *Intensive Care Medicine* 51 (1): 179-81.  
<https://doi.org/10.1007/s00134-024-07718-8>.

LETTER



# Effects of delayed consent on patient characteristics in adult patients with sepsis

Frank Bloos<sup>1</sup> , Holger Bogatsch<sup>2</sup>, Mihai G. Netea<sup>3,4</sup> , Evangelos J. Giamarellos-Bourboulis<sup>5</sup> and Michael Bauer<sup>1\*</sup> on behalf of the SepNet Critical Care Trials Group

© 2024 The Author(s)

Dear Editor,

Obtaining the patient's informed consent is a fundamental ethical prerequisite for clinical trials. However, sepsis patients frequently lose their ability to give informed consent. The short inclusion windows in emergency care usually render it impossible to designate and inform a legal representative in time. Therefore, the concept of a "deferred consent" has been introduced [1], albeit some investigators argue this might violate the patient's right to participate of their own free will. Consequently, state authorities and ethical boards may insist on restricting research to patients capable of giving informed consent [2].

As we were confronted with this issue when designing the IMMUNOSEP-trial (ClinicalTrials.gov-ID NCT04990232), we aimed to describe patients' characteristics and outcome depending on the informed consent process in a post hoc analysis, hypothesizing that patients with sepsis able to consent differ from those that are not. We conducted a post hoc analysis of the randomized multicenter trials MAXSEP, SISPECT, and CandiSep, all with interventions not affecting mortality [3–5]. The informed consent process is outlined in supplementary table 1.

SISPECT (1089 patients), MAXSEP (550 patients), and CandiSep (342 patients) contributed to a total of 1981 analyzed patients. Of these, 1574 (79.5%) patients were

unable to give consent, while 407 (20.5%) patients gave consent themselves. Patients unable to give informed consent were either enrolled by obtaining consent from a legal representative ( $n=259$ , 16.5%) or by a deferred consent process ( $n=1315$ , 83.5%). Of the 16,105 patients assessed for eligibility, 568 patients (3.5%) were excluded as informed consent could not be obtained. Baseline characteristics stratified by status of consent are reported in supplementary table 2. Pneumonia and intraabdominal infections were the most frequent underlying infections, with pneumonia occurring more often in the "unable" and urogenital infection more often in the "able" group. Patients unable to give informed consent had higher lactate concentrations and were more likely on mechanical ventilation and vasopressor support as also reflected in higher Sequential Organ Failure Assessment (SOFA) scores. Mortality was significantly higher in the "unable" compared to the "able" group (Fig. 1), albeit "renal replacement-free days" were paradoxically and unexpectedly lower in those able to give consent.


The pooled data from these multicenter trials show marked differences in outcome depending on the ability to give informed consent. Thus, enrollment of critically ill patients into trials remains an ethical challenge where validity of the results needs to be weighed against patient autonomy. The European Union (EU) regulation No 536/2014 allows to enroll patients without informed consent in emergency situations. This, however, inflicts additional challenges as informed consent needs to be obtained later. In this case, a legal representative has to stand for the patient's presumed will or the patient consents after regaining the appropriate mental ability, which is impossible in case of early death. Results would be heavily biased when study participation depends on time to death. As an alternative, restricting enrollment

\*Correspondence: michael.bauer@med.uni-jena.de

<sup>1</sup> Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany

Full author information is available at the end of the article

A complete list of members of the study group is provided in the acknowledgements.



to patients able to give informed consent would fully preserve patient autonomy, but would severely affect external validity.

#### Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1007/s00134-024-07718-8>.

#### Author details

<sup>1</sup> Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany. <sup>2</sup> Institute for Medical Informatics, Statistics and Epidemiology (IMISE) and Clinical Trial Centre Leipzig, University of Leipzig, Leipzig, Germany. <sup>3</sup> Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands. <sup>4</sup> Department of Immunology and Metabolism, Life and Medical Sciences Institute, University of Bonn, Bonn, Germany. <sup>5</sup> 4th Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.

#### Acknowledgements

The members of the SepNet Critical Care Trials Group are: University Hospital Augsburg, Dept. of Anesthesiology and Surgical Intensive Care Medicine, Ulrich Jaschinski, MD; Simon Philipp, MD, Augsburg, University Hospital Bonn Division of Intensive Care Medicine, Dept. of Anesthesiology and Intensive Care Medicine, Christian Putensen, MD, Bonn, University Hospital Dresden, Dept. of Anesthesiology and Intensive Care Therapy, Maximilian Ragaller, MD, Dresden, University Hospital Greifswald, Dept. of Anesthesiology and Intensive Care Medicine, Mathias Gründling, MD; Sven Olaf Kuhn, MD, Greifswald, Hospital Martha-Maria Halle-Dölau, Dept. of Anesthesiology, Intensive Care Medicine and Pain Therapy, Harald Fritz, MD, Halle (Saale), University Hospital Hamburg-Eppendorf, Dept. of Intensive Care Medicine, Dominik Jarzacak, MD; Geraldine de Heer, MD; Stefan Kluge, MD; Axel Nierhaus, MD, Hamburg, University Hospital Heidelberg, Dept. of Anesthesiology, Johann Motsch, MD; Daniel C. Richter, MD, Heidelberg, Jena University Hospital, Dept. of Anesthesiology and Intensive Care Medicine, Michael Bauer, MD; Frank Bloos,

MD; Daniel Thomas-Rüddel, MD, Jena, University Medical Center Kiel, Dept. of Anesthesiology and Intensive Care Medicine, Gunnar Elke, MD; Dirk Schaedler, MD; Norbert Weiler, MD, Kiel, University of Leipzig Medical Centre, Dept. of Anesthesiology and Intensive Care Medicine, Gunther Hempel, MD; Sebastian Stehr, MD, Leipzig, LMU Klinikum, LMU Munich, Department of Anesthesiology, Joseph Briegel, MD, Munich, University Hospital Münster, Dept. of Anesthesiology, Surgical Intensive Care Medicine and Pain Therapy, Raphael Weiss, MD, Münster, Carl von Ossietzky Universität Oldenburg, Research Center Neurosensory Science, Andreas Weyland, MD, Oldenburg, University Hospital Würzburg, Dept. of Anesthesiology, Emergency and Pain Medicine, Patrick Meybohm, MD, Würzburg, University Hospital Tübingen, Dept. of Internal Medicine, Reimer Riessen, MD, Tübingen

#### Funding

Open Access funding enabled and organized by Projekt DEAL.

#### Data availability

Data availability is settled by the original trials mentioned in references [3–5].

#### Open Access

This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Accepted: 26 October 2024

Published: 12 December 2024

## References

1. Fost N, Robertson JA (1980) Deferring consent with incompetent patients in an intensive care unit. *IRB* 2:5–6
2. van der Graaf R, Hoogerwerf M-A, de Vries MC (2020) The ethics of deferred consent in times of pandemics. *Nat Med* 26:1328–1330
3. Brunkhorst FM, Oppert M, Marx G et al (2012) Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. *JAMA* 307:2390–2399
4. Bloos F, Trips E, Nierhaus A et al (2016) Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial. *JAMA Intern Med* 176:1266–1276
5. Bloos F, Held J, Kluge S et al (2022) (1 → 3)- $\beta$ -D-Glucan-guided antifungal therapy in adults with sepsis: the CandiSep randomized clinical trial. *Intensive Care Med* 48:865–875